Plasma 1,5-anhydro-D-glucitol as new clinical marker of glycemic control in NIDDM patients

Yamanouchi, Toshikazu; Minoda, Susumu; Yabuuchi, Masahiko; Akanuma, Yasuo; Akanuma, Hiroshi; Miyashita, Hideo; Akaoka, Ieo

doi:10.2337/diabetes.38.6.723

Cited by 49 publications

(14 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In pigs, hemoglobin contains very little HbA1c due to the limited glucose permeability of erythrocytes (Higgins et al 1982). Normally, 1,5-AG is filtered and completely reabsorbed in the kidney (Yamanouchi et al 1989). In diabetes with elevated blood glucose levels, glucose is not completely reabsorbed in the kidney, so serum 1,5-AG is decreased due to competitive inhibition in renal tubular reabsorption (Yamanouchi et al 1992(Yamanouchi et al , 1996.…”

Section: Discussionmentioning

confidence: 98%

Dominant-negative mutant hepatocyte nuclear factor 1α induces diabetes in transgenic-cloned pigs

Umeyama¹,

Watanabe²,

Saitô

et al. 2009

Transgenic Res

View full text Add to dashboard Cite

Pigs have been recognized as an excellent biomedical model for investigating a variety of human health issues. We developed genetically modified pigs that exhibit the apparent symptoms of diabetes. Transgenic cloned pigs carrying a mutant human hepatocyte nuclear factor 1alpha gene, which is known to cause the type 3 form of maturity-onset diabetes of the young, were produced using a combined technology of intracytoplasmic sperm injection-mediated gene transfer and somatic cell nuclear transfer. Although most of the 22 cloned offspring obtained died before weaning, four pigs that lived for 20-196 days were diagnosed as diabetes mellitus with nonfasting blood glucose levels greater than 200 mg/dl. Oral glucose tolerance test on a cloned pig also revealed a significant increase of blood glucose level after glucose loading. Histochemical analysis of pancreas tissue from the cloned pigs showed small and irregularly formed Langerhans Islets, in which poor insulin secretion was detected.

show abstract

Section: Discussionmentioning

confidence: 98%

Dominant-negative mutant hepatocyte nuclear factor 1α induces diabetes in transgenic-cloned pigs

Umeyama¹,

Watanabe²,

Saitô

et al. 2009

Transgenic Res

View full text Add to dashboard Cite

show abstract

“…1,5‐Anhydroglucitol is filtered in the glomerulus and physiologically almost completely reabsorbed in the proximal tubules in competition with glucose. Consequently, in presence of hyperglycemia above the renal threshold, 1,5‐AG is excreted in the urine and circulating serum concentrations of 1,5‐AG decrease . Various studies have shown that with advanced renal failure (eGFR <30 mL/min), renal processing of 1,5‐AG is impaired and does not adequately reflect the metabolic situation in these patients .…”

Section: Discussionmentioning

confidence: 99%

Effect of renal function on serum concentration of 1,5‐anhydroglucitol in type 2 diabetic patients in chronic kidney disease stages I–III: A comparative study with HbA1c and glycated albumin

Hasslacher

Kulozik

2016

Journal of Diabetes

View full text Add to dashboard Cite

show abstract

“…This beneficial effect on hyperglycemia was demonstrated precisely by the mean ± SD values of the glucose levels monitored with CGMS together with the 1,5-AG levels that reflect glycemic excursions, often in the postprandial state, more robustly than HbA1c or fructosamine measurements [25,26]. …”

Section: Discussionmentioning

confidence: 99%

A pilot study of the efficacy of miglitol and sitagliptin for type 2diabetes with a continuous glucose monitoring system and incretin-related markers

Kishimoto

Noda

2011

Cardiovasc Diabetol

View full text Add to dashboard Cite

BackgroundGlucose fluctuations including robust postprandial hyperglycemia are a risk for promoting atherosclerosis and diabetic complications. The α-glucosidase inhibitors and the dipeptidyl peptidase-4 (DPP-4) inhibitors have been found to effectively decrease postprandial hyperglycemia independently. Therefore, glycemic control with the combination of these drugs is warranted.MethodsContinuous glucose monitoring (CGM) was performed for 3 patients with type 2 diabetes and 1 control subject from the beginning to the end of the study. Medications were not administered to any of the subjects on the first day of the study. From the second day to the end of study (days 2-5), the subjects received miglitol (150 mg per day) and on days 4 and 5, sitagliptin (50 mg per day) was added to the treatment regimen. On the first, third, and fifth days of the study, blood was drawn at 0, 30, 60, 120, 180, and 240 min after breakfast for measurements of serum insulin, 1,5-anhydroglucitol (1,5-AG), plasma glucagon, glucagon-like peptide-1 (GLP-1), and glucose-dependent insulinotropic peptide (GIP).ResultsMeasurements of CGM and 1,5-AG levels showed that miglitol attenuated the escalation and fluctuation of glucose levels, and this was even more pronounced with the combination of miglitol and sitagliptin. The patterns of insulin secretion and glucagon secretion with miglitol alone or with a combination of miglitol and sitagliptin were various in the study subjects. Miglitol alone enhanced the release of GLP-1 in 1 patient with type 2 diabetes and the control subject, whereas the combination of miglitol and sitagliptin increased GLP-1 levels to varying degrees in all the subjects. Except for 1 subject, none of the subjects showed any change in GIP levels after the addition of sitagliptin, compared to the administration of miglitol alone.ConclusionsIn conclusion, CGM measurements revealed that a combination of the α-GI miglitol and the DPP-4 inhibitor sitagliptin effectively reduced postprandial glucose fluctuation and stabilized blood glucose levels. Completely different response patterns of insulin, glucagon, GLP-1, and GIP were observed among the study subjects with either medication alone or in combination, suggesting that individual hormone-dependent glycemic responses to the α-GI and DPP-4 inhibitors are complicated and multifactorial.

show abstract

Plasma 1,5-anhydro-D-glucitol as new clinical marker of glycemic control in NIDDM patients

Cited by 49 publications

References 0 publications

Dominant-negative mutant hepatocyte nuclear factor 1α induces diabetes in transgenic-cloned pigs

Dominant-negative mutant hepatocyte nuclear factor 1α induces diabetes in transgenic-cloned pigs

Effect of renal function on serum concentration of 1,5‐anhydroglucitol in type 2 diabetic patients in chronic kidney disease stages I–III: A comparative study with HbA1c and glycated albumin

A pilot study of the efficacy of miglitol and sitagliptin for type 2diabetes with a continuous glucose monitoring system and incretin-related markers

Contact Info

Product

Resources

About